Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
101.01%
-
Total 13F principal
-
$560,212,900
-
Principal change
-
+$223,790
-
Total reported market value
-
$566,449,836
-
Number of holders
-
40
-
Value change
-
-$1,604,582
-
Number of buys
-
20
-
Number of sells
-
16
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q2 2024
As of 30 Jun 2024,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
40 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$560,212,900
in principal (par value) of the bond.
The largest 10 bondholders included
BRAIDWELL LP, Graham Capital Management, L.P., Linden Advisors LP, Weiss Asset Management LP, ADVENT CAPITAL MANAGEMENT /DE/, ARISTEIA CAPITAL, L.L.C., 683 Capital Management, LLC, Point72 Asset Management, L.P., LAZARD ASSET MANAGEMENT LLC, and Affinity Asset Advisors, LLC.
This page lists
41
institutional bondholders reporting positions
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.